Experimental cell therapy for advanced gynecological tumors shows early promise but study halted
NCT ID NCT06834542
First seen May 06, 2026 · Last updated May 22, 2026 · Updated 5 times
Summary
This early-phase study tested a personalized immune cell therapy called GT201 in one person with advanced gynecological tumors. The treatment uses the patient's own tumor-fighting cells to try to shrink tumors. The study was stopped early, so results are very limited and no conclusions can be drawn about safety or effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT GYNECOLOGICAL TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Jiaotong University School of Medcine, Renji Hospital Ethica Committee
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.